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a b s t r a c t
A new chemical entity, which is a chiral indane dimer, PH46A, has been developed by our research group.
As a clinical candidate. PH46A has recently completed Phase I clinical studies in man. Previously, during
its pre-clinical development, in in vivo pre-clinical studies PH46A showed potent anti-inﬂammatory
properties, which can be targeted at a range of diseases, including inﬂammatory bowel disease (IBD).
To support the pre-clinical development of this drug candidate, we developed a LC MS/MS method
for determining PH46 (the acid form of PH46A salt) in both dog and rat plasma using Compound 1 as
internal standard (IS). Those species were selected for safety pharmacology and toxicology, as well as
pharmacokinetics studies.
The method was validated over the range 10−10000 ng/mL for both matrices and the linearity, accuracy,
precision and speciﬁcity over this range were demonstrated to be acceptable. No signiﬁcant matrix effects
or carryover were observed for both PH46 and IS and recovery was consistent. PH46 was found to be
stable in both dog and rat plasma under the test conditions, such as at room temperature for >24 h,
through 3 freeze/thaw cycles, and at -20 ◦ C for >1 month. PH46 and IS in dog and rat plasma extracts
were also found to be stable in the autosampler against fresh standard extracts on re-injection after
143.5 h and 243.5 h, respectively at 4 ◦ C. 10- and 100-fold dilutions with control matrix were found not
to affect the performance of the assay. This method was successfully applied to a pharmacokinetic study
in the dog. With the exception of one dog, 003 M, oral administration of PH46A in gelatine capsules was
well tolerated at a dose level of 100 mg/kg. The highest Cmax was observed in animal 003 M. The rapid
absorption and high plasma concentration observed for animal 003 M compared to the data for animals
001 M and 002 M may account for the sickness observed in this animal; however, the reasons for this
have not been investigated.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).

1. Introduction
Our research group have developed a series of indane dimers
and the biological activities of these molecules have been
investigated [1–6]. During the course of our work, a novel
indane scaffold was discovered which demonstrated potential
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treatment of inﬂammatory conditions, in particular inﬂammatory bowel disease (IBD) [7]. A lead, ﬁrst-in-class molecule,
PH46A, 6-(methylamino)hexane-1,2,3,4,5-pentanol-4-(((1S,2S)1-hydroxy-2,3-dihydro-1H,1 H-[2,2-biinden]-2-yl)
methyl)
benzoate [8,9] has been shown to have a biological effect in
two different well-established preclinical models of murine colitis:
the acute dextran sodium sulphate model and the chronic and
spontaneous Interleukin-10 (IL-10−/− ) knock-out mouse model
[8]. This is indicative that PH46A has a therapeutic effect which
is independent of model speciﬁc aetiology. Based on the effects
in the animal models, PH46A is believed to be a potential new

https://doi.org/10.1016/j.jpba.2019.113011
0731-7085/© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Chemical structures of PH46A, PH46 and Compound 1 (IS).

treatment for patients with IBD and it has recently completed a
Phase I clinical trial study in healthy volunteers [10].
The in vitro comparative metabolism study of PH46A that we
recently published showed that PH46A metabolism in rat is most
similar to human, and all putative human metabolites are present
in rat, dog, mouse and cynomolgus monkey [11]. Rat and dog were
therefore selected as appropriate and useful species for use in
subsequent mandatory and pivotal GLP safety pharmacology and
toxicology studies in order to guide the clinical development of
PH46A. Further, at this time, studies in laboratory animals provide the best available basis for extrapolation to humans and are
required to support regulatory submissions. Acceptable models
which do not use live animals currently do not exist. The rat was
selected as the test model, since it is accepted by regulatory authorities as a rodent animal model for toxicity studies [12], high quality
animals are readily available, and a large amount of background
pathology data is available in this species. The dog was also selected
as the test model to meet regulatory requirements for testing in a
non-rodent species [12] and because of the availability of background data and the proven suitability in toxicology studies. As
part of the preclinical investigations, the characterisation of the
pharmacokinetics (PK) of PH46A in the rat and the dog were studied. To this end, this manuscript describes the development and
validation of sensitive and speciﬁc LC–MS analytical methods for
determining PH46 (the free acid form of PH46A salt) (Fig. 1) in
dog and rat plasma according to the Food and Drug Administration (FDA) [13] and the European Medicines Agency (EMA) [14]
guidelines. The method was subsequently applied to a PK study in
male Beagle dogs to quantitate levels of PH46 and evaluate its oral
bioavailability following oral administration of PH46A in capsule.
2. Materials and methods
2.1. Chemical and reagents
PH46A [purity 97.1 %; correction factor (purity and salt content): 0.6429] and Compound 1 as Internal Standard (IS, Fig. 1)
(purity 99.8 %) were obtained from Trino Therapeutics Ltd (Ireland).
Control rat (Sprague Dawley) and dog (Beagle) plasma and blood
were obtained from Charles River Laboratories (UK) using lithium
heparin as anticoagulant and stored at -20 ◦ C when not in use
(all control plasma was mixed and centrifuged prior to use). HPLC
grade solvents and additives, including methanol (MeOH), acetonitrile (ACN), water, ammonia solution, acetic acid (AA), acetone,
dimethylsulphoxide (DMSO), chloroform and formic acid (FA),
were purchased commercially between VWR (Ireland) and SigmaAldrich (Ireland) and were used without further puriﬁcation. Size
12 gelatine capsules (Torpac ‘Loc Ring Capsules’, USP grade) were
used to administer the dose for the pharmacokinetic study.

Table 1
Quality control data relating to PH46 in dog and rat plasma (results expressed as
ng/mL).
PH46 in dog plasma

Batch
7
Batch
12
Batch
17
Batch
18
Mean
Precision (%)
Accuracy (%)

PH46 in rat plasma

25.0*

300*

8000*

24.4
22.9
22.9
27.7
24.1
25.7

319
316
298
330
337
330

8120
8730
9130
8550
8100
8610

–

–

–

24.6
7.5
98.5

322
4.3
107.2

8540
4.6
106.8

25.0*

300*

8000*

–

–

–

–

–

–

–

–

–

24.2
23.2
23.7
n/a
94.8

306
302
304
n/a
101.3

7930
8480
8210
n/a
102.6

*
Nominal concentration of PH46. Precision: coefﬁcient of variation of mean.
Accuracy: mean determined concentration/nominal concentration. n/a: not applicable.

2.2. Animals and husbandry
All animal research work reported in this article have been carried out in accordance with Directive 2010/63/EU and its Irish
transposition S.I No 543 of 2012. Ethical approval was obtained
through Trinity College Dublin which complies with the Council for International Organizations of Medical Sciences’ (CIOMS),
International Guiding Principles for Biomedical Research Involving Animals, and all laws, regulations and policies governing the
care and use of laboratory animals in the jurisdiction in which
the research is being conducted. Three male Beagle dogs (onstudy numbers: 001 M, 002 M and 003 M, respectively) body weight
9.9–11.2 kg, were supplied by Charles River Laboratories (UK). During pre-trial and on-study periods, the animals were gang housed
in cages appropriate to the species. Prior to inclusion on this study,
animals were subject to a veterinary examination and the results
found to be satisfactory. All animals were weighed prior to each
dose administration and body weights recorded. Animals were
fasted overnight prior to dosing and offered standard laboratory
diet (PM1 Lab Diet 5007, Purina) for 2 h post-dose. Mains quality
tap water was available ad libitum throughout the study.
2.3. Instrumentation and operation conditions
AB Sciex API 3000 LC/MS/MS System consisted of HPLC pump
(Series 200, Perkin Elmer), autosampler (HTS Pal, CTC Analytics),
column oven (Series 200, Perkin Elmer) and six-port switching
valve (Valco). Operations and data analysis were controlled by
data handling system (Analyst Version 1.4.2, AB Sciex) and Laboratory Information Management System (Watson 7.0, Thermo

n = 3 7633624.1
n = 3 5099520.4
88.8
n = 3 4530866.7
87.5

n = 3 7452637.7

n=3
n = 3 361785.4

n = 3 6517584.8

85.6
n = 3 309814.5

3
*Nominal concentration of PH46. Extracted samples = PH46 and IS extracted from plasma. Matrix extracts = PH46 and IS spiked into extract from blank plasma. Recovery = Mean extracted peak area/mean matrix extract peak area.
n = replicates. n/a = not applicable.

n = 3 5505430.4
n = 3 6205135.6
n = 3 6912293.9
110.4

n = 3 422655.8
88.3
n = 3 373108.5
n/a

n=3

n = 3 33549.4
n=3
n/a
n=3
87.2

n = 3 29225.5

112.7

n=3
n/a
n=3

n/a
n=3
99.3

n = 3 33775.9

extracted samples

n = 3 25490.6

IS in dog

extracted samples
matrix extracts

PH46 in dog

Control plasma sample (Lithium Heparin anticoagulant) was
removed from the freezer and allowed to thaw at room temperature. Control matrix was vortex mixed and centrifuged prior to
use. 50 L was added to each appropriate well of a clean round
bottomed 96 well plate for double blank (DB) (control matrix
only without PH46/IS) and single blank (SB)control matrix with
IS only) samples. CSs, QCs and test samples were removed from
the freezer and allowed to thaw at room temperature and vortex
mixed prior to aliquoting. 50 L was added to each appropriate
well of a clean round bottomed well plate. 50 L of IS [0.3 g/mL
in MeOH/chloroform (50:50, v/v)] was added to all samples except
for DBs, which received 50 L of MeOH/chloroform (50:50, v/v). A
further 500 L of MeOH/chloroform mixture was added to all samples and the plate was sealed and vortex mixed thoroughly prior
to centrifugation (3500 rpm, 5 min, 4 ◦ C). The supernatant from all
samples was transferred into clean matrix tubes, dried under nitro-

extracted samples

2.6. Sample extraction

Table 2
Recoveries from dog and rat plasma samples of PH46 and IS (results expressed as peak areas).

The primary stock solutions of PH46 and IS were prepared at
1000 g/mL in ACN/DMSO (50:50, v/v). The calibration standards
(CSs) were prepared by serially diluting the primary PH46 stock
solution in control matrix to give concentrations at 10, 20, 65, 250,
750, 2500, 9000 and 10000 ng/mL plasma. For each batch of samples, aliquots (50 L) of CSs were extracted in duplicate to give
a range of concentrations of PH46 within the linear range of the
assay and a ﬁxed concentration of IS (300 ng/mL) prepared from
IS stock using MeOH/chloroform (50:50, v/v). Quality control (QC)
samples were prepared in control matrix from the primary PH46
stock solution in similar manner as CSs, to give QCs at 10 [Lower
Limit of Quantiﬁcation (LLOQ)], 25 (low), 300 (medium) and 8000
(high) ng/mL plasma concentrations and aliquots (50 L) of QCs
were extracted for analysis. All the solutions were stored at −20 ◦ C
and brought to room temperature before being analysed. A correction for batch speciﬁc purity was applied to all weighing, as well as
a correction for salt content (382.5/577.7; free acid/salt).

matrix extracts

2.5. Preparation of calibration standards and quality control
samples

25.0 ng/mL*Mean
Recovery (%)
300 ng/mL*Mean
Recovery (%)
8000 ng/mL*Mean
Recovery (%)

PH46 in rat

The haemolysed plasma was prepared by overtaxing and freezing an aliquot of the blood at −20 ◦ C for a short period of time. This
was then thawed, centrifuged (3500 rpm, 4 ◦ C & 10 min) and the
resultant plasma was transferred to a clean tube for use. All control
plasma was stored at −20 ◦ C when not in use and was mixed and
centrifuged prior to use.

matrix extracts

2.4. Preparation of control matrix

extracted samples

IS in rat

matrix extracts

Fisher Scientiﬁc). Halo C18 column (75 × 2.1 mm, 2.7 m, HiChrom)
and PreFrit Filter guard column (0.5 m, Anachem) was employed
at 60 ◦ C with autosampler temperature at 4 ◦ C. Mobile phase A:
MeOH:AA (100:0.2, v/v) and mobile phase B: water:AA (100:0.2,
v/v). The gradient was 40 % B (0 min), 20 % B (2.0 min), 20 % B
(4.0 min), 0 % B (4.5 min), 40 % B (4.7 min), 0 % B (4.9 min) and
40 % B (8.0 min). Flow rate was 0.3 mL/min with injection volume
of 10 L and run time of 8 min. The solvent mixtures for needle wash are MeOH/water/acetone/FA (40/40/20/1, v/v/v/v) and
MeOH/water/ammonia (50/50/1, v/v/v).
Mass spectrometric detection was performed using TurboIonSpray negative ionization mode. Standard API3000 nitrogen was
used for nebulizing and drying. Ion spray temperature was 550 ◦ C
and ion spray voltage was −4500 V. The probe positions were 5 mm
(X) and 5 mm (Y). PH46 ion monitored was 381.10 → 135.10 (± 0.5)
dwell 150 msec and IS ion monitored was 379.10 → 134.14 (± 0.5)
dwell 150 msec.

n=3
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n=6
9020
8.2
112.8

n=6
8260
4.4
103.3

n=6
8110
4.1
101.4
8070
8.1
100.9
n=6
9130
5.5
114.1
8740
8.0
109.3

2.7. Validation procedures
The analytical method was developed and validated for use on
the Tomtec robotic pipetter using 96 well plates and matrix tubes
in a 96 well format. Since the test sample PH46A was weighed and a
correction factor was use for the salt content, all peak area measurement and determined concentrations reported were for PH46 acid.
Each batch of samples consisted of matrix DB, matrix SB, CSs, QC and
test sample extracts. One set of CSs was injected at the start of the
run and one set at the end of the run. CSs were injected in concentration order in each section of the run. QC samples were prepared
in control matrix at low, medium and high levels (n≥2 at each level).
Where n = 2, one low & one medium level QC samples were injected
at the start of the run after one set of CSs, and one low & one high
level QC samples were injected at the end of the run before the other
set of CSs. The remaining medium & high QCs were injected midway
through the run. Where n>2, the additional QCs were appropriately
distributed throughout the run. Solvent or extracted matrix DBs
were injected after high concentration extracts prior to injecting
a potentially low concentration extract in order to avoid the risk
of assay carryover. The target acceptance criteria for QCs was that
the determined concentrations of at least 66 % of QCs in each batch
had to be within 100 ± 15 % of the nominal concentrations, including at least one QC sample at each concentration had to meet this
criterion.

n=6
319
1.6
106.3

n=6
8070
3.3
100.9

3
2

n=6
311
0.9
103.7
n=6
25.9
2.2
103.6
n=6
26.1
5.6
104.4
n=6
10.1
6.2
101.0

Nominal concentration of PH46.

PH46 in rat plasma

n=6
8.60
12.6
86.0

n=6
10.1
9.0
101.0
9.56
9.7
95.6
n=6
9.18
10.4
91.8
9.28
11.3
92.8
n=6
9.69
10.0
96.9
PH46 in dog plasma

*

1

n=6
7830
13.3
97.9
n=6
327
1.4
109.0

3

gen at 60 ◦ C and then reconstituted in 200 L of MeOH/water/AA
(50:50:0.2, v/v/v). The extracts were vortex-mixed and centrifuged
for 5 min at 3500 rpm at 4 ◦ C.

n=6
314
2.6
104.7
314
5.6
104.7
n=6
332
5.5
110.7
321
4.5
107.0

2

n=6
300
7.5
100.0
n=6
23.6
2.9
94.4

n=6
25.4
3.2
101.6
24.3
7.8
97.2
n=6
25.5
3.8
102.0
25.8
4.0
103.2

1
3
2

n=6
23.9
12.5
95.6

2
1
Occasion

Replicate
Intra-assay Mean
Intra-assay precision (%)
Intra-assay accuracy (%)
Inter-assay Mean
Inter-assay precision (%)
Inter-assay accuracy (%)
Replicate
Intra-assay Mean
Intra-assay precision (%)
Intra-assay accuracy (%)
Inter-assay Mean
Inter-assay precision (%)
Inter-assay accuracy (%)

3

1

300 ng/mL*
25 ng/mL*
10 ng/mL*

Table 3
Intra- and inter-assay accuracy and precision for PH46 in dog and rat plasmas (results expressed as peak areas).

n=6
8.93
7.0
89.3

8000 ng/mL*

4

2.7.1. Stability of PH46 and IS in stored stock solutions
The effect of PH46 storing stock solutions in ACN/DMSO (50/50,
v/v) at 4 ◦ C was investigated by comparison of peak area ratios of
freshly weighed stock solutions with stock solutions which had
been prepared 35 days previously. Both stock solutions were prepared in the same way. The stock solutions were diluted to the
one upper limit of quantiﬁcation (ULOQ) level with an appropriate diluent. The effect of storing solutions of IS (working and
stock solutions) in ACN/DMSO, (50/50, v/v) for the stocks and
MeOH/chloroform (50/50, v/v) for the working solution at 4 ◦ C was
investigated by comparison of peak area ratios of freshly weighed
and diluted stock and working solutions with solutions which had
been prepared 35 (stocks) and 27 (working solutions) days previously. PH46 and IS were deemed to be stable if the mean detector
responses for the stored solutions were within 100 ± 10 % of the
mean detector responses of the freshly prepared solutions and the
precision is ≤10 %. The effect of storing stock solutions of PH46
in ACN/DMSO (50/50, v/v) at ambient room temperature was also
studied by comparison of peak area ratios of an aliquot of the stock
solution stored at 4 ◦ C with an aliquot of the same stock solution
stored at ambient room temperature for 24 h. Both solutions were
diluted to the ULOQ level with an appropriate diluent. PH46 was
expected to be stable at room temperature if the mean detector
responses for the solutions stored at room temperature were within
100 ± 10 % of the mean detector responses of the solutions stored
at ca 4 ◦ C and the precision is ≤10 %.
2.7.2. Speciﬁcity and linearity
The assay speciﬁcity was determined by extraction and analysis
of six different sources of the matrix (different batches of matrix
were pooled from different animals). For each source, the samples were prepared, including one DB (control matrix only), one
SB (control matrix + IS), one LLOQ (IS only) and ULOQ (without IS).
If interfering peaks at the retention times (RTs) of PH46 or IS were
noted, these were deemed to be insigniﬁcant if the response at RT of
PH46 was ≤20 % of the response in LLOQ samples and if the response
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Fig. 2. Calibration curves for the determination of PH46 in dog (upper) and rat (lower) plasma.

Table 4
Effects of dilution of PH46 with dog and rat plasmas (results expressed as ng/mL).
Dilution of PH46 with dog plasma
Dilution factor
Replicate
Mean
Precision (%)
Accuracy (%)

Dilution of PH46 with rat plasma
10
n=6
68200
13.2
85.3

100
n=6
73500
2.8
91.9

at the RT of IS was ≤5 % of the IS response. The 16-point calibration curves over 10−10000 ng/mL were constructed by plotting the
peak area ratio of PH46:IS against the nominal matrix concentrations of PH46 to determine the optimum regression parameters.
The matrix concentration of PH46 from each of CSs was calculated
from the corresponding curve. A DB sample and a SB sample were
also extracted and analysed, these were not included in the regression analysis. The acceptance criteria were that at least 75 % [a
minimum of 6 including at least one LLOQ and one ULOQ sample] of
the standards had to be back-calculated to be within 100 ± 15 % of
the nominal concentrations (100 ± 20 % at LLOQ). Conﬁrmation of
linearity was performed at least on three separate occasions during
the validation.

10
n=6
74600
3.8
93.3

100
n=6
73700
7.7
92.1

2.7.3. Assay recovery and matrix effect
The matrix effects were determined by extracting replicate
(n = 6) samples of control matrix, from six individual sources
(one of these sources was haemolysed plasma which matched
one of the non-haemolysed sources), and PH46 & IS solutions in
MeOH/water/AA (50:50:0.2, v/v/v) were spiked after extraction.
This resulted in replicate matrix effect samples (n = 3) at each of
the matrix equivalent PH46 concentrations of 25 and 8000 ng/mL
and IS concentration of 3000 ng/mL. Replicate (n = 3) non-extracted
QC samples were prepared in the same ratio as the extract samples. The matrix factor (MF) for PH46 and IS was determined in
each source of matrix by calculating the ratio of the mean response
of replicate samples spiked into matrix to the mean response of

6
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Fig. 3. Chromatograms of a dog plasma extract (left) containing PH46 (LLOQ, 10 ng/mL) & IS (3000 ng/mL) and a dog plasma extract (right) containing PH46 (ULOQ,
10000 ng/mL) & no IS.

Table 5
Stability tests of PH46 in dog & rat plasma (results expressed as ng/mL).
PH46 concentration in dog plasma

PH46 concentration in rat plasma

25*

8000*

25*

8000*

a.
Replicate (n=6)
Mean
Precision (%)
Accuracy (%)

Baseline 3 Cycles

Baseline 3 Cycles

Baseline 3 Cycles

Baseline 3 Cycles

b.
Replicate (n=6)
Mean
Precision (%)
Accuracy (%)

Baseline
23.6
2.9
94.4

25.1
4.3
100.4

8260
4.4
103.3

7670
5.2
95.9

25.5
3.8
102.0

27.7
6.4
110.8

9130
5.5
114.1

c.
Replicate (n=6)
Mean
Precision (%)
Accuracy (%)

Baseline

31 days

Baseline

31 days

Baseline

30 days

Baseline

23.6
2.9
94.4

25.1
10.6
100.4

8260
4.4
103.3

7900
2.3
98.8

25.5
3.8
102.0

25.4
4.4
101.6

9130
5.5
114.1

d.
Replicate (n=6)
Mean
Precision (%)
Accuracy (%)

Baseline

143.5 h

Baseline

143.5 h

Baseline

243.5 h

Baseline

25.4
3.2
101.6

25.1
10.6
100.4

8110
4.1
101.4

7630
6.4
95.4

26.1
5.6
104.4

26.1
5.9
104.4

8070
3.3
100.9

e.
Replicate (n=6)
Mean
Precision (%)
Accuracy (%)

10*

25*

300*

8000*

10*

25*

300*

8000*

9.75
11.6
97.5

25.2
11.9
100.8

296
7.2
98.7

7500
13.7
93.8

8.71
11.0
87.1

25.4
7.9
101.6

318
1.8
106

8310
5.3
103.9

23.6
2.9
94.4

25.5
3.6
102.0
24 h

8260
4.4
103.3
Baseline

8000
4.0
100.0
24 h

25.5
3.8
102.0
Baseline

26.4
3.1
105.6
24 h

9130
5.5
114.1
Baseline

8650
9.1
108.1
24 h
91205.
5.1
114.0
30 days
8420
6.6
105.3
243.5 h
7410
4.0
92.6

*Nominal concentration of PH46.
a. Freeze/thaw stability test; b. Ambient temperature stability test; c. Short term frozen matrix storage stability test; d. Autosampler stability (plasmas extract stored at 4 ◦ C);
e. Reinjection stability.
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Fig. 4. Chromatograms of a rat plasma extract (left) containing PH46 (LLOQ, 10 ng/mL) & IS (3000 ng/mL) and a rat plasma extract (right) containing PH46 (ULOQ, 10000 ng/mL)
& no IS.
Table 6
Pharmacokinetic parameters of PH46 in male beagle dog plasma following PH46A oral capsule administration of 100 mg/kg.
Dog

001M
002M
003M
n
Mean*
SD

Cmax
(ng/mL)

7960
21100
34900
3
21300
13500

Cmax /D
(ng/mL)/
(mg/kg)
79.6
211
349
3
213
135

Tmax (h)

AUC(0-t)
(ng.h/mL)

2.00
2.00
0.750
3
2.00
-

22200
51100
31700
3
35000
14700

AUC(0-t) /D
(ng.h/mL)/
(mg/kg)
222
511
317
3
350
147

AUC(0-inf)
(ng.h/mL)

22000
51000
n/r
2
36900
-

AUC(0-inf)
/D
(ng.h/mL)/
(mg/kg)

T1/2 (h)

224
513
n/r
2
369
-

5.72
5.03
n/r
2
5.38
-

*Median for Tmax . n/r = Not reported, the coefﬁcient of determination < 0.800.

the non-extracted samples. The IS-normalised MF was calculated
by dividing PH46-MF by IS-MF from the same source. No matrix
effect in the samples was expected if the precision of the ISnormalised MF calculated from the six sources was ≤15 %. The assay
recovery was determined by preparing, extracting and analysing
replicate (n = 3 at low, medium and high levels) matrix effect
samples from a single source of matrix (spiked after extraction).
Replicate (n = 3) extracted samples were prepared, extracted and
analysed as detailed in Section 6.10 at the same low, medium and
high concentrations as the matrix effect samples. The recoveries of
PH46 and IS were deﬁned as the mean responses in the extracted
samples/the mean responses in the matrix effect samples.
2.7.4. Intra- and inter-batch assay accuracy and precision
The assay intra- and inter-batch accuracy and precision were
evaluated using replicate (n = 6) QC samples at 10 (LLOQ), 25
(low), 300 (medium) and 8000 (high) ng/mL. The intra- and inter
accuracy expressed as the mean percentage determined concentration/nominal concentration, which was expected to be within

100 ± 15 % at each concentration level (100 ± 20 % at LLOQ level).
Intra- and inter-precision were determined by the coefﬁcient of
variation of the mean determined concentration, which should be
≤15 % at each level (≤20 % at LLOQ level). The intra-batch assay
accuracy and precision were determined on three occasions and a
different batch of mobile phase was used on each occasion; three
batches at each level were used for inter-batch assays.
2.7.5. Assay carryover and matrix dilution
Carryover was assessed by using replicate QCs (n = 2) at LLOQ &
ULOQ levels and additional replicate (n = 2) DBs. The sequence of
analysis was: 1 x ULOQ, 2 x DBs, 1 x LLOQ, 1 x ULOQ, 2 x solvent
samples (SSs) (MeOH/water/AA, 50:50:0.2, v/v/v) and 1 x LLOQ. No
assay carryover for PH46 can be concluded if the PH46 responses
in DB and SS were ≤20 % of the detector responses for PH46 in the
following LLOQ samples; no IS carry-over if the IS responses in DB
and SS were ≤5 % of the detector responses for IS in the preceding
ULOQ samples. Replicate (n = 6) QC samples were made by diluting
10- and 100-fold of a bulk stock (80000 ng/mL in control matrix).
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Fig. 5. The plasma concentration proﬁles (upper: liner plot & lower: semi-log plot) of PH46 in male beagle dog following oral capsule administration of 100 mg/kg PH46A.

Aliquots (50 L) (n = 6 of each dilution factor) were then extracted
(nominal concentrations of 8000 and 800 ng/mL). The determined
concentrations were corrected for the dilution factors. Matrix dilution was considered to be acceptable if the assay accuracy was
within 100 ± 15 % and the assay precision was ≤15 %.

2.7.6. Stability experiments
Six aliquots (50 L) of QCs at each low (25 ng/mL) and high
(8000 ng/mL) concentration levels were extracted and analysed
to conﬁrm the suitability of the stability samples. Freeze/thaw
stability of PH46 in matrix was performed using replicate QCs samples (n = 6) at each concentration level receiving three freeze/thaw
cycles at −20 ◦ C (initial freeze cycle at least 24 h, cycles 2 and 3 at
least 12 h and thaw cycle for an hour at room temperature).
Ambient room temperature stability of PH46 in matrix was
assessed on further QCs (n = 6) at each level after left at ambient
temperature for 24 h before extraction with fresh CSs and QCs.

Short term matrix frozen storage stability was achieved by
analysing replicate QCs (n = 6) at each concentration after one
month’s storage at −20 ◦ C.
Low and high QC samples extracted and previously injected for
accuracy and precision batches (occasion two for dog plasma and
occasion one for rat plasma) were re-injected for autosampler stability. The extracts had been stored at 4 ◦ C for 143.5 h and 243.5 h
for dog and rat batches respectively.
Reinjection stability was assessed by using the occasion 1 accuracy and precision batches, having stored the extracts at 4 ◦ C for
131.5 h and 129.5 h for dog and rat batches respectively.
All stability samples were processed and quantiﬁed against
freshly spiked CS and freshly spiked QC samples. The samples
were considered to be stable if the mean determined concentration/nominal concentration was within 100 ± 15 % and the
coefﬁcient of variation was ≤15 % at each concentration level for
each stability experiment.
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2.8. Data processing and calculations

9

Data collection carried out during this study was performed
using Analyst Version 1.4.2 data handling software. Determination of the calibration parameters (slope, intercept and coefﬁcient
of determination) and the calculation of mean, standard deviation
and accuracy data were performed using Thermo Fisher Scientiﬁc
WatsonTM Version 7.0 software. The nominal matrix concentrations of CS and QC samples were entered to three signiﬁcant ﬁgures.
Determined concentration data are determined to three signiﬁcant
ﬁgures. For the CS and QC sample data, mean values were calculated from the unrounded determined concentration data and are
presented rounded to three signiﬁcant ﬁgures. Accuracy data were
calculated from the rounded mean values and are presented to one
decimal place. Precision data were calculated from the unrounded
determined concentration data and peak area data and are presented rounded to one decimal place. Slopes and intercepts are
presented to four signiﬁcant ﬁgures; coefﬁcients of determination
are presented to four decimal places. Peak area ratios are presented
to six decimal places.

Occasion 3, where y: the peak-area ratio of PH46 to IS; x: the plasma
concertation of PH46. For PH46 in rat plasma, A: -0.000000004036,
B: 0.0001640, C: 0.0002521 and R2 : 0.9977 for Occasion 1; A: 0.000000005498, B: 0.0002251, C: 0.0007108 and R2 : 0.9996 for
Occasion 2; A: -0.000000004418, B: 0.0002091, C: 0.0003914 and
R2 : 0.9941 for Occasion 3. All determined concentrations for these
standards met the acceptance criteria. The representative calibration curves from Occasion 2 are presented in Fig. 2.
The QC sample data for the supporting QC samples are presented
in Table 1, which met the acceptance criteria of the determined concentrations being within 100 ± 15 % of the nominal concentration.
The assay speciﬁcity demonstrated there were no signiﬁcant interfering substances at the RTs of PH46 and IS. A peak at RT of IS was
observed in the PH46 chromatograms in samples containing IS due
to in-source breakdown of IS. This did not interfere with the PH46
peak as both peaks were well resolved. A peak was also observed
at RT of IS in samples containing only PH46, however, it was ≤5 %
of the IS response and was therefore within acceptable limits. Representative chromatograms of dog plasma and rat plasma extracts
are shown in Figs. 3 and 4, respectively.

2.9. Pharmacokinetic study in dog

3.3. Assay recovery and matrix effects

The PH46A capsules were prepared the day before the dosing by
weighing a suitable amount of PH46A into each capsule to achieve
a target dose level of 100 mg/kg. The capsule ﬁll weights were
1077.4 mg, 1119.6 mg and 990.4 mg for Capsule 1 (001 M), Capsule
2 (002 M) and Capsule 3 (003 M), respectively. Each capsule was
administered by placing it in the back of the throat of each animal
followed by swallowing and visual conﬁrmation that the capsule
was swallowed. Following dosing, blood samples (1 mL) were collected from the jugular vein into tubes containing lithium heparin
as an anticoagulant at the following sampling times: pre-dose, 0.25,
0.75, 1, 2, 4, 6, 8, 12 and 24 h post-dose. Plasma was separated by
centrifugation (3000 rpm, 10 min & 4 ◦ C) prior to storage at −80 ◦ C
until analysis. Individual PH46 plasma concentrations generated
were used to estimate pharmacokinetic parameters using WinNonLin v4.1 pharmacokinetic software.

For PH46 and IS in dog and rat plasma, the recoveries were consistent (Table 2). For PH46 and IS in dog plasma, at PH46 of 25 ng/mL
the IS-normalised MFs from all six sources were 1.094, 1.131, 1.149,
1.111, 1.198, 1.071 and the corresponding precision was 4.0 %. At
8000 ng/mL level, the MFs were 1.248, 1.296, 1.312, 1.250, 1.382,
1.357 and the associate precision was 4.2 %. For PH46 and IS in
rat plasma, the MFs at PH46 of 25 ng/mL were found to be 1.079,
1.028, 1.067, 1.054, 1.122, 1.029 and the precision was 3.3 %. At
8000 ng/mL level, the MFs were 1.383, 1.262, 1.273, 1.263, 1.358,
1.261 and the precision was 4.3 %. These results demonstrated that
the matrix effects met the acceptance criteria and no signiﬁcant
matrix effect was present for PH46 and IS in both dog and rat plasma
by the current method.

3. Results and discussion

The intra-batch accuracy and precision of the assay for PH46
in dog and rat plasma met the acceptance criteria for each of the
three batches at each of the four concentrations assessed (Table 3).
The inter-batch accuracy and precision also meet the acceptance
criteria on each occasion.

3.1. Stability of PH46 and IS in stored stock solutions
Both PH46 and IS stock solutions were found to be stable for at
least 35 days at 4 ◦ C, IS working solutions for at least 27 days at 4 ◦ C
for, and PH46 stock solutions for at least 24 h at room temperature.
3.2. Speciﬁcity and linearity
The calibration data from both dog plasma (8 batches) and rat
plasma (7 batches) standards (over a range of 10−10000 ng/mL,
duplicate run at each concertation) were analysed. In all cases at
least 75 % of standards (and a minimum of 12 standards, including at least one replicate at the LLOQ and ULOQ levels) used to
construct each calibration line met the acceptance criterion of the
determined concentrations being within 100 ± 15 % of the nominal concentrations (100 ± 20 % of the nominal concentration at
the LLOQ). Regression analysis of the peak area ratios of PH46:IS
against the concentration demonstrated good linearity for dog and
rat plasma over the range 10−10000 ng/m using a quadratic regression with a weighting factor of 1/x. For PH46 in dog plasma, the
mean values of the regression equation y = Ax2 +Bx + C were A: 0.000000007620, B: 0.0003271, C: 0.0002245 and R2 (coefﬁcient
of determination): 0.9986 for Occasion 1; A: -0.000000004671, B:
0.0001919, C: 0.0002627 and R2 : 0.9998 for Occasion 2 and A: 0.000000004328, B: 0.0002098, C: 0.0005037 and R2 : 0.9991 for

3.4. Intra- and inter-assay accuracy and precision

3.5. Assay carry-over and matrix dilution
No signiﬁcant carry-over was observed in the matrix blank and
solvent samples injected after a ULOQ sample for PH46 or IS in
both dog and rat plasma. The accuracy and precision for samples
prepared at 80000 ng/mL and diluted at 10- and 100-fold met the
acceptance criteria for dog and rat plasma (Table 4). These results
showed that 10- and 100-fold dilutions of samples in control dog
or rat plasma had no effect on the accuracy and precision of the
method.
3.6. Stability experiments
Data from all the stability test for both dog and rat plasma are
shown in Table 5. All results met the acceptance criteria and PH46A
and IS were stable in dog and rat plasma under current stability
test conditions. It was concluded that PH46 and IS are stable in dog
and rat plasma extracts under the following conditions: at least
three freeze/thaw cycles at −20 ◦ C, at least 24 h at ambient temperature, at least 31 days and 30 days, respectively at −20 ◦ C, and
143.5 h and 243.5 h respectively at the auto-sampler temperature
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of at 4 ◦ C before being re-injected. The mean re-injection stabilities
of PH46 in extracts of dog and rat plasma stored at 4 ◦ C for 131.5 h
and 129.5 h respectively, also met the acceptance criteria.
3.7. Pharmacokinetic study
No adverse reactions to treatment were observed when dogs
001 M and 002 M were dosed orally, while animal 003 M produced
some frothy vomit at about 0.5 h post-dose and further yellow liquid vomit at 1.5 h post-dose. The animals were fed ca 2 h post-dose
and after this period no further vomiting was observed. Except
for these incidences of emesis, there were no other reactions to
treatment.
The pharmacokinetic parameters are presented in Table 6
and the pharmacokinetic proﬁles are represented graphically in
Fig. 5. Maximal concentrations observed were variable within
the 3 animals, with the highest concentration (Cmax ) observed
in animal 003 M (34900 ng/mL). Tmax was 2 h for animals 001 M
and 002 M, however, Tmax for 003 M was 0.75 h. The half-life
of elimination (T1/2 ) was similar in animals 001 M and 002 M
(003 M not measurable) with a mean of 5.4 h. The mean AUC(0-t)
was 35000 ± 14700 ng.h/mL and mean AUC (0-inf) was similar at
36900 ng.h/mL (n = 2).
4. Conclusion
A sensitive and speciﬁc analytical method was developed and
validated for the determination of PH46 in dog and rat plasma. A
range of testing, including linearity, accuracy, precision, speciﬁcity,
matrix effect, carry-over, dilution effect and stabilities, were established for both matrices. The method meets EMA validation criteria.
This method was successfully applied to a pre-clinical pharmacokinetic study in dog.
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